Chemists' org warns against Centre's plan to expand OTC drug list
2
Shillong: The
All India Organisation of Chemists and Druggists
has cautioned against the Centre's proposal to classify more medicines as over-the-counter (OTC) products, maintaining that this would have harmful effects on the health of the people.
In a statement issued on Friday, the
Meghalaya Healthcare Association
, which is a unit of the AIOCD, cautioned the potentially dangerous consequences of this move and pointed out that medicines, even those used routinely, require expert supervision to avoid harmful effects.
"Paracetamol is widely used as a pain reliever, but an overdose can cause serious liver and kidney damage," David Kharsati, president of the Association said in the statement and also highlighted the risks of diclofenac, a common anti-inflammatory drug available in potassium and sodium forms.
"These two variants must be prescribed carefully, especially for patients with blood pressure issues. Interchanging them without proper guidance can worsen the condition," he said. He added while the govt may aim to simplify access, expanding the OTC list could disrupt the existing supply chain and lead to confusion among consumers.
The AIOCD, which represents around 12.5 lakh chemists across India, also raised concerns about the growing financial strain on local pharmacies and cited the rise of online pharmacies and govt-supported schemes like Jan Aushadhi and Dawa India as major factors behind declining business margins.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
Quality drive at govt health units runs into ‘missing data' problem
New Delhi: The Union government has doubled down on attempts to enforce quality at government-run health facilities after a recent review meeting heard that state governments were supplying "missing, inconsistent and outdated' data, holding back the Centre's efforts. Accurate data is needed for the Center to roll out National Quality Assurance Standards (NQAS) certification, a set of standards for assessing and certifying the quality of public health facilities in India. The National Health Mission's (NHM) funding for states and union territories is conditional on their health facilities getting the necessary NQAS certification. Seized of the issue, the Union health ministry is asking all states and union territories to promptly update their health facility information on the National Identification Number (NIN) portal–the central repository for all hospital data. The problem has left the Centre facing difficulties mapping health facility data on the SaQsham portal, which is essential for issuing NQAS certification. The portal requires accurate and complete hospital data, including location details and a unique NIN ID. According to a letter from the health ministry, the issue was a key challenge highlighted during the NQAS implementation review meeting. 'The SaQsham Portal, designed to digitize and streamline the NQAS certification, relies on accurate and complete facility-level data, including block name, taluka, district, and unique NIN ID, sourced via APIs from the NIN Portal,' said the letter sent to all states and union territories. 'However, observations reveal that data on the NIN ID Portal is often "missing, inconsistent, or outdated," which is hampering the ability of States/UTs to effectively map their health facilities and consequently delaying certification and reporting activities under NQAS,' said the letter seen by Mint. To boost healthcare quality, the government has mandated NQAS certification for all public health facilities, including district hospitals, community health centres, and primary health centers (both rural and urban), along with Ayushman Arogya Mandirs, formerly known as Ayushman Bharat Health & Wellness Centres, that provide primary healthcare services to all citizens. The health ministry is working towards certifying 50% of these facilities by the end of 2025, with a broader goal of certifying all of them by December 2026. Out of 175,000 health facilities targeted for quality certification by the next year, only 22,787 had achieved NQAS certification by December last year. According to a Lancet report from 2018, India could potentially save a significant number of lives by improving the quality of healthcare. The study indicated that about 1.6 million deaths each year in the country are linked to substandard care, and that providing quality healthcare could prevent three out of five of these fatalities. There haven't been any newer studies in India on this specific issue since then. Queries sent to the health ministry spokesperson remained unanswered.
Time of India
4 hours ago
- Time of India
Central team in Kerala to visit Nipah-affected areas
Malappuram (Kerala): A central team arrived in Kerala on Wednesday to visit Nipah-affected areas in two northern districts and coordinate preventive efforts. The National Joint Outbreak Response Team, appointed by the Union Ministry of Health and Family Welfare, visited Malappuram district to study the Nipah situation, report it to the Centre, and assist the state in preventive measures, official sources here said. Besides Malappuram, another case of Nipah infection was reported from neighbouring Palakkad district. Dr Pranay Verma, the Joint Director and Public Health Specialist at the National Center for Disease Control (NCDC), is leading the 10-member expert team, an official statement said here. The team also includes scientists from the ICMR-National Institute of Virology, Pune, wildlife specialists, veterinary consultants, and experts from the animal welfare department. They met District Medical Officer (DMO) Dr R Renuka and held discussions. Another National Institute of Virology (NIV) team of eight members led by Dr E Dilip Patil will soon arrive in the district to monitor and survey bats. This team is currently based in Palakkad, the statement added. Meanwhile, the Palakkad native, infected with Nipah virus, continues to remain at the government medical college in Kozhikode, sources said. Another patient, a Malappuram native, succumbed to the virus infection last week. State Health Minister Veena George said as many as 498 people are in the Nipah contact list in Kerala at present. Of this, 203 people are in Malappuram, 116 in Kozhikode, 177 in Palakkad, and two in Ernakulam, she said in a statement here. The test result of a 78-year-old woman, who was on the contact list of a person who died of the virus infection in Malappuram recently, has turned out to be negative, she said. During a high-level meeting conducted on Wednesday, the Minister ordered that preventive measures according to the Nipah calendar be vigorously continued until September. PTI>
Business Standard
7 hours ago
- Business Standard
Apollo AyurVAID Launches India's First 'Tested Safe' Ayurveda Products
NewsVoir Bengaluru (Karnataka) [India], July 10: Apollo AyurVAID, India's leading NABH-accredited, precision Ayurveda hospital network, announces its strategic foray into the Ayurveda product segment, marking a significant expansion beyond clinical care. The new portfolio spans classical formulations, OTC products, and medical foods, crafted to meet the growing demand for safe, clinically validated Ayurveda products in India's ~ Rs. 60,000 crore market growing at over 16% annually. In an industry first, Apollo AyurVAID's product range features clinically proven formulations that are certified safe by NABL-accredited laboratories with respect to presence of heavy metals, aflatoxins, microbial content, etc., as applicable for different product types. Apollo AyurVAID's products set the highest, proof-backed, safety benchmark in the Ayurveda product market with the consumer able to verify test results (QR code on packaging) for each and every product they consume. This reinforces Apollo AyurVAID's resolve to offer safer, standardised, and effective Ayurveda products that the market can implicitly trust. Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals and Chairperson, Apollo AyurVAID said, "Apollo AyurVAID's foray into tested-safe Ayurveda products marks a pivotal step in redefining standards of safety, transparency, and efficacy in traditional medicine. This expansion builds on a strong foundation of clinical excellence and reflects a deep commitment to evidence-based, precision Ayurveda. By integrating innovation with time-honoured wisdom, Apollo AyurVAID is well on its way to shaping the future of integrative medicine in India and beyond." Commenting on this strategic initiative, Mr. Rajiv Vasudevan, Founder, MD, and CEO, Apollo AyurVAID said, "With two decades of clinical excellence behind us, we are extending our understanding of precision Ayurveda and credibility into a high-potential consumer space. This new vertical not only complements our inpatient-outpatient care model but also opens scalable revenue opportunities and reinforces our vision of mainstreaming evidence-based Ayurveda services and products by making it accessible globally. We anticipate this portfolio will be a key growth driver, with a revenue aspiration of Rs. 500 crores in the next 5 years." The Ayurveda products division is being developed as a business unit of Apollo AyurVAID, while staying firmly rooted in Apollo AyurVAID's commitment to precision Ayurveda for personalised, safe, clinical-outcomes-driven health care.. While classical formulations will be available through prescription, the OTC and medical foods lines will be available through a wide network of retail and digital platforms. The OTC range features innovative medicine formats such as creams, transdermal pads, essential extracts, etc., for special customer segments (women, child, elder, etc.) and applications (pain, sleep, stress, skin etc.), with highest medical content assuring best-in-class product performance. Apollo AyurVAID has recently partnered with integrated systems biology platform company, Avesthagen Limited, to co-develop and offer scientifically validated, botanical-actives based dietary supplements that are sugar-free, artificial colour & flavours free; this shall be followed with an Ayurveda based medical foods range for specific clinical indications. The classical and OTC product range are branded 'AyurVAID' while the dietary supplements are branded 'AvestaAyurVAID'. This strategic expansion reinforces Apollo AyurVAID's vision of building a credible, science-led ecosystem for precision Ayurveda and evolving into a full-spectrum Ayurveda company. "As we enter the Ayurveda products space, our broader vision is to take the Apollo AyurVAID brand across the length and breadth of India. In the current fiscal we plan to expand our hospital network in an asset-light manner by adding 9 new points of presence, scaling our bed capacity to 350, aiming to treat over 50,000 patients. With a CAGR of 75% over the last 2-3 years, we are on track to surpass the annualised Rs. 100 crore revenue mark by mid next year - an unprecedented milestone in Ayurveda's services sector. This is just the beginning of our journey to take Apollo AyurVAID, India's most credible, precision Ayurveda care, to every corner of the country and across the globe," added Mr. Rajiv Vasudevan. Distribution for the new portfolio will follow a multi-tier strategy, with availability across Apollo AyurVAID's hospitals and clinics, the company's website, Apollo Pharmacies, Apollo 24|7 and leading e-commerce platforms. This integrated channel approach is designed to enable access and reach to a wider audience. Apollo AyurVAID ( is India's leading chain of protocol-driven Ayurveda hospitals and integrative care centres, delivering evidence-based, 'Precision Ayurveda' for chronic disease reversal, management, and sustained wellbeing. Since its inception in 2005, Apollo AyurVAID has been committed to transforming Ayurveda into a mainstream, protocols, documentation and clinical-outcomes driven system of medicine with hospitals and clinics spread across Bengaluru, Chennai, New Delhi, Kochi, Almora and Hyderabad. Founded in 2005 and part of the Apollo group since 2022, Apollo AyurVAID has emerged as a pivotal force in formalising Ayurveda-led integrative care, developing a unique care model that combines traditional Ayurvedic wisdom with modern clinical rigour. The chain of hospitals has demonstrated an impactful model of integrative care across specialties including neurology, oncology, nephrology, obstetrics and gynaecology, and metabolic disorders, with a focus on adjuvant therapy, palliative care, rehabilitation, and primary intervention. Apollo AyurVAID's unique 'Whole Person Care' approach considers the whole person to treat multimorbidity, not just at symptom level but at root-cause level, and supports health across the entire life cycle, from prevention and treatment to rehabilitation, survivorship and wellbeing. The first and only Ayurveda institution to receive the prestigious QCI DL Shah National Quality Award (2012), Apollo AyurVAID is also India's first NABH-accredited Ayurveda hospital (2010). It is also the first to gain NABH accreditation for Ayurveda para surgery (2013) and five hospitals in its countrywide network are NABH-accredited. In 2023, it became the first and only QAI-accredited Ayurveda and integrative medicine based Transition Care Centre in India.
